Hims Hers Health Inc (HIMS)vsTeva Pharma Industries Ltd ADR (TEVA)
HIMS
Hims Hers Health Inc
$28.00
-4.21%
HEALTHCARE · Cap: $6.05B
TEVA
Teva Pharma Industries Ltd ADR
$34.43
-2.47%
HEALTHCARE · Cap: $41.13B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 632% more annual revenue ($17.35B vs $2.37B). TEVA leads profitability with a 9.0% profit margin vs -0.6%. TEVA appears more attractively valued with a PEG of 0.87. TEVA earns a higher WallStSmart Score of 66/100 (B-).
HIMS
Avoid27
out of 100
Grade: F
TEVA
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-7.0%
Fair Value
$25.38
Current Price
$28.00
$2.62 premium
Intrinsic value data unavailable for TEVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
Trading at 14.5x book value
3.8% revenue growth
Distress zone — elevated risk
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : HIMS
HIMS has a balanced fundamental profile.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.87 suggests the stock is reasonably priced for its growth.
Bear Case : HIMS
The primary concerns for HIMS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.54 is elevated, increasing financial risk.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
HIMS profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.
HIMS carries more volatility with a beta of 2.42 — expect wider price swings.
HIMS is growing revenue faster at 3.8% — sustainability is the question.
HIMS generates stronger free cash flow (53M), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (66/100 vs 27/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Hims Hers Health Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. The company is headquartered in San Francisco, California.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?